Growth Hormone Stimulation Test: At-Home and Finger-Prick Options, Normal Ranges, and Optimal Targets

What Is a Growth Hormone Stimulation Test and Why Is It Necessary?

A random serum GH level is nearly useless in clinical practice. GH is secreted in brief, irregular pulses, and basal concentrations between pulses can fall below 0.1 ng/mL in healthy adults. A stimulation test applies a physiological or pharmacological challenge, then measures whether the pituitary can mount a peak GH response above a validated threshold. This distinguishes true GH deficiency from the normal pulsatile nadir.

The Endocrine Society's 2019 clinical practice guideline states directly: "We recommend confirming the diagnosis of AGHD biochemically with a GH stimulation test in all but a few specific clinical situations." [1] That guideline specifically names the insulin tolerance test (ITT) and the glucagon stimulation test (GST) as historically accepted standards, with macimorelin added to the list following FDA approval in 2017. [2]

Why Random GH Tests Fail

GH half-life in serum is approximately 20 minutes. A blood draw taken 40 minutes after a secretory burst may show a value indistinguishable from GH deficiency. Studies using 24-hour pulsatile sampling show that healthy young adults spend roughly 70% of the day at GH concentrations below 0.5 ng/mL. [3] This is why no single random draw, finger-prick or venous, can substitute for a properly provoked test.

The Role of IGF-1 as a Surrogate

Insulin-like growth factor-1 (IGF-1) is produced primarily in the liver under GH stimulation. Because IGF-1 has a half-life of 15 to 20 hours, its serum concentration reflects integrated GH secretion over the preceding days rather than a single pulse. The Endocrine Society notes that a very low IGF-1 (standard deviation score below -2.0) in the right clinical context may support the diagnosis without full stimulation testing, but a normal IGF-1 does not exclude GH deficiency. [1] IGF-1 can be measured from dried blood spot cards at home, making it the most practical at-home monitoring tool available today.

At-Home and Finger-Prick Options for Growth Hormone Assessment

True at-home growth hormone stimulation testing, meaning a provoked peak GH measurement without a clinic visit, is not yet commercially available as a validated consumer product. The stimulation protocols currently approved or guideline-endorsed require controlled fasting conditions, time-series blood collection, and calibrated immunoassay equipment. What is available at home falls into two distinct categories.

Dried Blood Spot (DBS) IGF-1 Testing

DBS cards allow patients to lance a fingertip, deposit three to five drops of blood onto absorbent filter paper, allow the card to dry, and mail it to a CLIA-certified laboratory. Studies validating DBS IGF-1 against venous serum IGF-1 show correlation coefficients of 0.93 to 0.97 when using modern tandem mass spectrometry methods. [4] LabCorp and several specialty labs currently accept DBS specimens for IGF-1 and IGFBP-3 quantification.

DBS IGF-1 is best used for:

• Baseline screening before deciding whether a stimulation test is needed.
• Longitudinal monitoring of patients already on GH replacement therapy.
• Telemedicine-based follow-up between in-clinic visits.

DBS is not a substitute for the stimulation test when the clinical question is whether the pituitary can produce GH on demand.

Venous Draw Through Mobile Phlebotomy

Several mobile phlebotomy services, including Getlabs and Labcorp Mobile, can perform timed venous draws at a patient's home or office. For the macimorelin test specifically, the protocol requires only two blood draws: one at baseline and one at 30 minutes after the oral dose. A trained phlebotomist arriving at a patient's home with a chilled collection kit and a supervised oral macimorelin dose makes the test far less burdensome than a clinic visit. This is not a finger-prick procedure, but it eliminates hospital or outpatient lab travel for patients with mobility limitations or those in rural areas.

Wearable and Microfluidic Research Platforms

Stanford and MIT groups have published proof-of-concept microfluidic devices capable of detecting GH in sweat and interstitial fluid. [5] These platforms are not FDA-cleared and are not available commercially as of mid-2025. They are mentioned here so readers understand the direction of the field rather than to suggest current clinical use.

Normal Range vs. Optimal Range for the Growth Hormone Stimulation Test

Understanding the difference between a "normal" result and an "optimal" result is central to how functional and longevity-medicine practitioners interpret GH testing. The two thresholds serve different clinical purposes.

Diagnostic Cutoffs (Normal Range)

The FDA-approved label for macimorelin (Macrilen) sets the deficiency threshold at a peak GH response below 3 ng/mL using a body mass index-independent cutoff. [2] This replaced the older ITT cutoff of 3 ng/mL and the GST cutoff of 3 ng/mL, which had been used inconsistently across assay platforms.

The 2019 Endocrine Society guidelines specify:

• ITT: peak GH <5 ng/mL indicates severe GH deficiency in most assay systems.
• Macimorelin: peak GH <3 ng/mL, FDA-cleared, recommended when ITT is contraindicated.
• Glucagon stimulation: peak GH <3 ng/mL, acceptable alternative. [1]

Obesity substantially suppresses GH responses. A patient with a BMI above 30 kg/m² may show a peak GH of 1.5 ng/mL on ITT despite having an anatomically normal pituitary, simply because excess adiposity amplifies somatostatin tone and blunts GH release. [6] Some expert centers apply obesity-adjusted cutoffs, though no consensus threshold has been universally adopted.

Optimal Targets in Longevity and Functional Medicine

The concept of an "optimal" GH stimulation response extends beyond diagnosing deficiency. Practitioners focused on age-related GH decline use stimulation testing to identify patients whose GH axis is intact but suppressed by modifiable factors, including poor sleep, obesity, physical inactivity, elevated insulin, or hypothyroidism.

In studies of healthy young adults aged 18 to 30, peak GH responses to arginine or GHRH-arginine provocation average 20 to 30 ng/mL. [7] By age 60, the same protocol produces average peaks closer to 8 to 12 ng/mL in lean, healthy individuals, reflecting normal somatopause. A result between 3 and 11 ng/mL in a middle-aged patient occupies a gray zone: technically not deficient by diagnostic criteria, but substantially below the response seen in younger cohorts.

The HealthRX clinical team uses the following operational framework for interpreting stimulation results in non-deficient adults seeking optimization:

| Peak GH Response | Interpretation | Suggested Next Step | |---|---|---| | <3 ng/mL | GH deficiency (diagnostic) | Confirm with second test or MRI pituitary; consider rhGH | | 3 to 7 ng/mL | Subnormal for age in most adults <60 | Address modifiable suppressors; consider GHRH/GHRP peptide protocols | | 7 to 11 ng/mL | Low-normal; age-dependent | Lifestyle optimization; reassess in 6 to 12 months | | >11 ng/mL | Adequate secretory capacity | No GH-axis intervention indicated |

These ranges are operational guidance informed by published normative data, not FDA-approved diagnostic thresholds.

Approved Stimulation Agents: Protocols, Doses, and Practical Notes

Macimorelin (Macrilen): The Most Patient-Friendly Option

Macimorelin is a ghrelin receptor agonist approved by the FDA in December 2017 specifically for diagnosing adult GH deficiency. [2] The dose is 0.5 mg/kg dissolved in 120 mL of water, taken orally after an overnight fast of at least 8 hours. A single blood draw at 30 minutes post-ingestion provides the diagnostic GH peak. The AGHD trial validating macimorelin (N=157) showed sensitivity of 92% and specificity of 96% at the 3 ng/mL cutoff versus the ITT as reference. [8]

Key considerations:

• Discontinue strong CYP3A4 inducers (rifampin, carbamazepine) at least 14 days before testing.
• Avoid fatty meals or food on the test day until after the 30-minute draw.
• QTc prolongation has been reported; obtain baseline ECG in patients with cardiac risk factors.

Insulin Tolerance Test (ITT)

The ITT remains the historical gold standard. Regular insulin 0.1 units/kg IV produces hypoglycemia (blood glucose below 40 mg/dL is required for a valid test), which drives a peak GH response through hypothalamic activation. [1] Because hypoglycemia is necessary and potentially dangerous, ITT is contraindicated in patients with seizure disorders, ischemic heart disease, or unexplained syncope. The ITT requires continuous medical supervision and cannot be adapted for home use.

Glucagon Stimulation Test (GST)

Glucagon 1 mg IM (1.5 mg for patients weighing above 90 kg) triggers GH release through a mechanism that likely involves counter-regulatory hypoglycemia and direct hypothalamic effects. Timed draws occur at 0, 30, 60, 90, 120, 150, and 180 minutes. The GST has a reported sensitivity of 97% and specificity of 88% at the 3 ng/mL threshold in a cohort of 60 adult patients with confirmed pituitary disease. [9] Nausea and vomiting affect roughly 20% of patients, which limits tolerability.

GHRH-Arginine Test

The GHRH-arginine combination (GHRH 1 mcg/kg IV plus arginine 0.5 g/kg IV over 30 minutes) was widely used before GHRH preparation became unavailable in the United States after 2008 due to manufacturing discontinuation. It remains available in Europe and parts of Asia. Body mass index-adjusted cutoffs are well-validated: peak GH below 11.5 ng/mL (BMI <25), below 8 ng/mL (BMI 25 to 30), and below 4.2 ng/mL (BMI >30). [1]

Confounders That Alter GH Stimulation Results

Several physiological and pharmacological states significantly affect GH responses and must be addressed before testing or factored into interpretation.

Obesity and Insulin Resistance

Adiposity reduces peak GH responses on all stimulation tests. A study of 49 obese adults (mean BMI 37 kg/m²) showed peak ITT GH responses 60% lower than in BMI-matched lean controls, with no difference in pituitary morphology on MRI. [6] Weight loss of 10% or more can substantially recover GH secretory capacity before retesting.

Thyroid and Glucocorticoid Status

Untreated hypothyroidism blunts GH secretion. Patients should be biochemically euthyroid (TSH within the normal range) before testing. Supraphysiologic glucocorticoid doses, including prednisone above 10 mg/day equivalent, suppress pituitary function and may produce false-positive deficiency results. [1]

Sex Steroids

Estrogen priming increases GH peak responses. Post-menopausal women tested without estrogen supplementation may show lower peaks than pre-menopausal women, even on identical protocols. Some centers prime all adult women with oral ethinyl estradiol 0.02 mg/day for 3 days before testing to standardize responses. [1] Testosterone levels in men also correlate with GH secretory amplitude; untreated hypogonadism should be addressed before attributing a blunted response solely to the GH axis.

Assay Standardization

GH immunoassays are not interchangeable across platforms. Results from different laboratories may differ by 30 to 50% for the same sample due to antibody specificity (22 kDa vs. 20 kDa GH isoforms) and calibration standards. [10] When interpreting results, verify which calibration standard the laboratory used, and apply the diagnostic cutoff specific to that assay platform.

IGF-1 and IGFBP-3: Supporting Biomarkers for At-Home Monitoring

IGF-1 and its binding protein IGFBP-3 are the most practical at-home monitoring tools for anyone tracking GH axis function. Because both can be measured from DBS finger-prick cards, they serve as accessible surrogates between formal stimulation tests.

IGF-1 Optimal Reference Ranges

IGF-1 declines with age and varies by sex. Published age-specific reference ranges from a population study of 3,961 adults show the following median values by decade [11]:

| Age Range | Men (ng/mL) | Women (ng/mL) | |---|---|---| | 20 to 29 | 215 to 380 | 185 to 335 | | 30 to 39 | 175 to 310 | 155 to 290 | | 40 to 49 | 140 to 270 | 120 to 255 | | 50 to 59 | 115 to 230 | 100 to 215 | | 60 to 69 | 90 to 195 | 85 to 185 | | 70 plus | 70 to 170 | 65 to 160 |

Longevity practitioners often target the upper quartile for a patient's age rather than simply the midpoint, though randomized evidence supporting any specific IGF-1 target for longevity outcomes is not yet available.

IGFBP-3

IGFBP-3 carries roughly 75 to 90% of circulating IGF-1 and is less sensitive to nutritional fluctuations than IGF-1 alone. An IGFBP-3 standard deviation score below -2.0 alongside a low IGF-1 significantly increases the pre-test probability of true GH deficiency before formal stimulation testing. [1]

When to Order a GH Stimulation Test vs. IGF-1 Alone

Choosing between a full stimulation test and an IGF-1 draw depends on clinical context. The Endocrine Society identifies three clinical settings where a stimulation test adds the most diagnostic value [1]:

1. Patients with hypothalamic or pituitary disease, surgery, or radiation who are being assessed for GH replacement eligibility.
2. Adults with childhood-onset GH deficiency who require re-testing after final height is reached to confirm persistent deficiency.
3. Adults with low IGF-1 and symptoms (fatigue, reduced lean mass, increased central adiposity, impaired quality of life) where replacing GH is under consideration.

IGF-1 alone is adequate for:

• Routine longitudinal monitoring once a patient is established on GH replacement.
• Population-level screening in functional medicine or longevity programs where stimulation testing would be impractical at scale.
• Adjusting GH replacement dose toward the target IGF-1 range specified by the Endocrine Society (maintain IGF-1 within the age-specific normal range, not exceeding the upper limit of normal). [1]

Interpreting Results in the Context of GH Replacement Therapy

Patients already taking recombinant human GH (somatropin, such as Norditropin, Genotropin, Humatrope, or Serostim) should not undergo stimulation testing to evaluate the GH axis during therapy. The administered GH suppresses endogenous pituitary secretion. Stimulation testing should occur only before initiating therapy or after a washout period agreed upon with the prescribing physician.

During therapy, the monitoring standard is:

• IGF-1 measured every 1 to 2 months during dose titration.
• IGF-1 every 6 months once a stable dose is reached.
• Annual fasting glucose and HbA1c because GH replacement reduces insulin sensitivity. [1]

A 2021 meta-analysis of 22 randomized controlled trials (total N=1,373) confirmed that GH replacement in adults with confirmed GH deficiency produced statistically significant improvements in lean body mass (weighted mean difference plus 1.6 kg, 95% CI 1.1 to 2.1 kg, P<0.001), fat mass reduction (minus 2.4 kg), and quality-of-life scores at 12 months, with no significant increase in cancer incidence over the study periods. [12]

Practical Steps to Prepare for a GH Stimulation Test

Preparation significantly affects result validity. Follow these steps before any provocation test:

1. Fast for at least 8 hours (water is permitted).
2. Avoid vigorous exercise for 24 hours before testing.
3. Discontinue GH replacement for at least 1 week (discuss washout with your physician).
4. Confirm thyroid function is within the normal range at least 4 weeks before testing.
5. Hold oral glucocorticoids where clinically safe; discuss with prescribing physician.
6. Arrive for the test at 8:00 to 9:00 AM, since GH secretion follows a diurnal pattern with highest amplitude overnight.
7. For the macimorelin test specifically: avoid grapefruit juice the morning of testing.

If using mobile phlebotomy for a macimorelin test at home, ensure the phlebotomist has a chilled specimen transport container and the pharmacy has dispensed the macimorelin kit in advance.